NASDAQ:AGLE - Aeglea Bio Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aeglea Bio Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.15 -0.21 (-2.51 %) (As of 02/18/2020 01:22 AM ET) Add Compare Today's Range$8.11Now: $8.15▼$8.4850-Day Range$7.08MA: $7.76▼$8.4852-Week Range$5.99Now: $8.15▼$9.10Volume26,515 shsAverage Volume53,311 shsMarket Capitalization$236.27 millionP/E RatioN/ADividend YieldN/ABeta1.08 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGLE Previous Symbol CUSIPN/A CIK1636282 Webhttp://www.aegleabio.com/ Phone512-942-2935Debt Debt-to-Equity Ratio0.06 Current Ratio6.02 Quick Ratio6.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.89 million Price / Sales60.74 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book2.90Profitability EPS (Most Recent Fiscal Year)($2.13) Net Income$-44,350,000.00 Net MarginsN/A Return on Equity-78.93% Return on Assets-67.63%Miscellaneous Employees61 Outstanding Shares28,990,000Market Cap$236.27 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive AGLE News and Ratings via Email Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AGLE Rates by TradingView Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions What is Aeglea Bio Therapeutics' stock symbol? Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE." How were Aeglea Bio Therapeutics' earnings last quarter? Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) issued its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.12. View Aeglea Bio Therapeutics' Earnings History. When is Aeglea Bio Therapeutics' next earnings date? Aeglea Bio Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Aeglea Bio Therapeutics. What price target have analysts set for AGLE? 2 brokers have issued 1-year price objectives for Aeglea Bio Therapeutics' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Aeglea Bio Therapeutics' stock price to reach $17.00 in the next year. This suggests a possible upside of 108.6% from the stock's current price. View Analyst Price Targets for Aeglea Bio Therapeutics. What is the consensus analysts' recommendation for Aeglea Bio Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aeglea Bio Therapeutics. What are Wall Street analysts saying about Aeglea Bio Therapeutics stock? Here are some recent quotes from research analysts about Aeglea Bio Therapeutics stock: 1. According to Zacks Investment Research, "Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. " (1/8/2020) 2. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for pegzilarginase in ARG1-D and our year end fully diluted net cash estimate of $2.55/share to arrive at our price target. We use the net present value of our revenue forecast through 2028, apply a 50% POS of pegzilarginase in 4x price/sales multiple for ARG1-D to arrive at a value of $4.40/share. We use a 20% discount rate for the NPV of the pipeline as it is within the typical range of 15-25% for products in development." (6/3/2019) Has Aeglea Bio Therapeutics been receiving favorable news coverage? Media coverage about AGLE stock has been trending very negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aeglea Bio Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Aeglea Bio Therapeutics. Who are some of Aeglea Bio Therapeutics' key competitors? Some companies that are related to Aeglea Bio Therapeutics include I-Mab (ARQT), Radius Health (RDUS), Amphastar Pharmaceuticals (AMPH), Stoke Therapeutics (STOK), Cytokinetics (CYTK), Homology Medicines (FIXX), Phathom Pharmaceuticals (PHAT), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), Rhythm Pharmaceuticals (RYTM), Collegium Pharmaceutical (COLL), CannTrust (CNTTF), Frequency Therapeutics (FREQ), DiaMedica Therapeutics (DMCAF) and Provention Bio (PRVB). What other stocks do shareholders of Aeglea Bio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea Bio Therapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Kura Oncology (KURA), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA) and Novavax (NVAX). Who are Aeglea Bio Therapeutics' key executives? Aeglea Bio Therapeutics' management team includes the folowing people: Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)Mr. Charles N. York II, CFO & VP (Age 42)Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 48)Mr. Eugene Sackett, VP of HR When did Aeglea Bio Therapeutics IPO? (AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Aeglea Bio Therapeutics' major shareholders? Aeglea Bio Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Marshall Wace LLP (2.88%), Renaissance Technologies LLC (1.99%), State Street Corp (1.60%), Goldman Sachs Group Inc. (1.53%), University of Texas Texas AM Investment Managment Co. (1.11%) and Comprehensive Portfolio Management LLC (0.84%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart, Anthony G Quinn and Bioventures Ltd Novartis. View Institutional Ownership Trends for Aeglea Bio Therapeutics. Which major investors are selling Aeglea Bio Therapeutics stock? AGLE stock was sold by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC, New York State Common Retirement Fund, Oxford Asset Management LLP, UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Aeglea Bio Therapeutics. Which major investors are buying Aeglea Bio Therapeutics stock? AGLE stock was purchased by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co., P.A.W. Capital Corp, California Public Employees Retirement System, State Street Corp, Marshall Wace LLP, Renaissance Technologies LLC, Barclays PLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Aeglea Bio Therapeutics. How do I buy shares of Aeglea Bio Therapeutics? Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Aeglea Bio Therapeutics' stock price today? One share of AGLE stock can currently be purchased for approximately $8.15. How big of a company is Aeglea Bio Therapeutics? Aeglea Bio Therapeutics has a market capitalization of $236.27 million and generates $3.89 million in revenue each year. The biotechnology company earns $-44,350,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe.View Additional Information About Aeglea Bio Therapeutics. What is Aeglea Bio Therapeutics' official website? The official website for Aeglea Bio Therapeutics is http://www.aegleabio.com/. How can I contact Aeglea Bio Therapeutics? Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected] MarketBeat Community Rating for Aeglea Bio Therapeutics (NASDAQ AGLE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 223 (Vote Outperform)Underperform Votes: 182 (Vote Underperform)Total Votes: 405MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe AGLE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: How much money do you need to begin day trading?
